Introduction
============

At present, there is growing evidence suggesting that microsatellite instability (MSI) may be one possible predictive marker of immunotherapy response in many cancer types and in malignant melanoma (MM) ([@b1-mco-0-0-1946]--[@b7-mco-0-0-1946]). The main cause of MSI is a defect in the DNA mismatch repair (MMR) genes, whose function is to repair the mismatched bases ([@b8-mco-0-0-1946]). Several repair genes (*MSH2, MSH3, MSH6, MLH1, MLH3, PMS1 and PMS2*) are involved in this process and work by forming heterodimers. The interaction between mismatch recognition complexes and other proteins such as helicase, proliferating cell nuclear antigen, replication protein A, exonuclease 1 is required for the rectification of base-pair alterations, insertion-deletion loops and hetero-duplexes instigated during replication and recombination ([@b9-mco-0-0-1946]). MMR genes aberrations can be investigated by immunohistochemistry (IHC) for MMR proteins, which is a quick and simple assay to recognize MMR status ([@b10-mco-0-0-1946]--[@b12-mco-0-0-1946]).

There is a clear relationship between the loss of IHC expression of one or more MMR proteins and the MSI phenomenon ([@b13-mco-0-0-1946],[@b14-mco-0-0-1946]). It was also known that the MSI status and the lack of MMR protein expression constitute a positive prognostic factor for colon cancer patients.

The reason of this evidence has been found in the enhanced immunogenicity of tumors characterized by MSI and MMR deficiency (MMR-d), because their defective ability to repair DNA damages lead to a higher mutational burden and an increased generation of neoantigens ([@b15-mco-0-0-1946]).

The involvement of MMR genes was proposed in MM tumorigenesis ([@b16-mco-0-0-1946]). MSI was described in displastic naevi, MMs and MM metastases, suggesting that the MMR system and consequently MSI could contribute to the pathogenesis of MM ([@b17-mco-0-0-1946]). Differently to colon cancer and other solid malignancies that are treated with immunotherapy ([@b1-mco-0-0-1946],[@b18-mco-0-0-1946],[@b19-mco-0-0-1946]), potential IHC biomarkers are still limited for MM up to now. This lack of predictive biomarkers for immunotherapy response in MM patients is today an important field of investigation, whose aim is to allow a personalized therapeutic approach. A targeted treatment in fact maximizes the patient\'s outcome, avoiding unnecessary risks for the patient\'s health and sparing important medical resources, because of the high costs of the new bioengineered drugs. The aim of our report was to evaluate the role of MMR IHC proteins expression as a predictive marker of immunotherapy response.

Patients and methods
====================

The study was conducted in accordance with the World Medical Association Declaration of Helsinki regarding ethical conduct of research. The study was regularly approved on October 2014 by the ethics committee of the University of Modena and Reggio Emilia and written informed consent was provided by patients for IHC analysis. As a part of a systematic review of the medical record of patients affected by advanced MM receiving anti PD-1 treatment from 2014 to 2016 at the Dermatology and Oncology Department of the University of Modena and Reggio Emilia, we collected the following data: Clinical stage of disease (AJCC 8th Ed., stage I--IV) ([@b20-mco-0-0-1946]); primary tumor location; overall survival (OS), progression-free survival (PFS) after anti PD-1 therapy; adverse events during anti PD-1 therapy. PFS was determined using the RECIST criteria ([@b21-mco-0-0-1946]).

IHC analysis of MSH6, MLH1, MSH2 and PMS2 proteins were carried out on the paraffin-embedded primary tumor samples of every included patients and on the available metastasis samples. The sections were cut (3--4 µm) into superfrost plus microscope slides and allowed to dry at 37°C overnight. The slides were submitted to antigen retrieval using microwave in 10 mmol/l citrate buffer, pH 6, at 350 W for 30 min. Immunoperoxidase staining, using diaminobenzidine as chromogen, was run with the NEX-ES Automatic Staining System (Ventana). Monoclonal antibodies anti-MSH6 (Clone 44; Transduction Laboratories; BD Biosciences) at 1:2,000, anti-MLH1 (G168-15) at 1:40, anti-MSH2 (G129-1129; both Pharmingen) at 1:40 dilution and anti PMS-2 (Biocare Medical) at 1:40 dilution were used. Nuclei were counterstained with hematoxylin and adjacent normal tissue in each sample served as positive control. The complete absence of staining of tumor cells for one of the MMR proteins was considered indicative of a mismatch repair defect.

Results
=======

We were able to identify 14 patients with advanced MM that were treated with anti PD-1 during 2014--2016 ([Table I](#tI-mco-0-0-1946){ref-type="table"}). Patients comprised 12 males and 2 females, average age was 71 years, ranging from 47 to 88 years. MM was located on the head and neck area (n=2, 14%), on the trunk (n=7, 50%), on the upper limb (n=3, 22%, of which 2 were acral) and on the lower limb (n=2, 14%, of which 1 was acral); no patient of our series was affected by mucosal melanoma. The total number of metastases was 45: 10 were located at the lungs, 8 at the lymph nodes, 6 at the skin, 3 in the retroperitoneum, 3 at the bone, 3 at the spleen, 3 at the liver, 3 at the brain, 2 at the muscle, 1 at the gut, 1 at the stomach, 1 at the pancreas and 1 at the kidney. Of these, only 23 were available as paraffin embedded samples.

Only three samples showed MMR-d of MMR genes, in particular of MSH6: they were one primary subungual melanoma and two metastases (brain and ileus) belonging to the same female patient, whose complex clinical history is summarized by the time plot represented in [Fig. 1](#f1-mco-0-0-1946){ref-type="fig"}. The IHC panels of the primary MM and related metastases of our MMR-d and of an exemplificative MMR normal patient are shown in [Figs. 2](#f2-mco-0-0-1946){ref-type="fig"} and [3](#f3-mco-0-0-1946){ref-type="fig"}, respectively. Remarkably, she showed the best response to anti PD-1 treatment of our cohort, with PFS and OS of 956 and 2,546 days, respectively. At present, the patient is still alive and in complete response. By contrast, MMR-s patients showed average PFS and OS of 290 and 542 days, respectively.

Discussion
==========

The assessment of MMR protein expression represents a potential predictive marker which may have crucial importance for primary and metastatic MM patients. The identification of quick and simple assays to predict the response to anti PD-1 agents is one of the goal that the new era of MM immunotherapy should achieve in order to satisfy the compelling objectives of a personalized medicine.

Several studies have demonstrated that MMR gene deficiency is a more widespread phenomenon than first assumed, being present in many tumor types, such as colon cancer, ovarian cancer, brain tumors, biliary tract tumors and gastric cancer, but also in neuroblastoma and endometrial cancer ([@b17-mco-0-0-1946]). In a recent study by Kim *et al* ([@b22-mco-0-0-1946]) the MMR-d tumor status was assessed in 430 consecutive solid tumors and was significantly correlated to the PD-L1 expression. Even though MMR-d is a negative biomarker for MM chemotherapy sensitivity ([@b23-mco-0-0-1946]), recent evidences suggest that it may be a positive biomarker for immunotherapy response. In detail, it was demonstrated that MSI, which is often a consequence of MMR gene deficiency, is associated to a better response to immunotherapy in terms of PFS. As a general consideration, our hypothesis is that the presence of a mutator tumor phenotype allows an easier escape of the tumor to the pharmacokinetis of conventional chemotherapy, but, on the other hand, it produces many neoantigens that increase the immunogenicity of tumor cells. Thus, it is our hypothesis that the IHC analysis of MMR gene could be a marker that predict PFS and OS of MM patients treated by anti-PD-1 agents. In our population, the best PFS response was reached by the patient that showed MMR-d tumor status, with lack of expression of MSH6, not associated to Lynch syndrome or Muir-Torre Syndrome. The clinical history of the patient was complex and the previous treatment lead to unsatisfactory results. Noteworthy, anti PD-1 therapy lead to a dramatic improvement of her management, with the regression of the brain and other metastasis, that are generally considered the prognostic factors that most negatively affect patient\'s survival. The limitations of our study consisted in the small population size and the lack of molecular biology investigations. Future studies are needed to investigate the role of MSI and MMR-d during immunotherapy in animal model as well as in larger patient cohorts.

In conclusion, the assessment of MMR protein expression represents a potential predictive marker, which may have crucial importance for primary and metastatic MM patients, mainly as criterion for the adoption of the immunotherapy treatments.
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![Patient history. (A) Clinical history schematic of a representative patient who exhibited a loss of MSH6 expression in primary subungual melanoma tissue and in ileal and brain metastasis tissue. (B) CT scan of the patient\'s brain, presenting metastasis that was present prior to PD-1 treatment. (C) Last CT scan of the patient, presenting regression of the metastasis (red arrow) after treatment with anti PD-1. Green boxes represent the drugs administered, blue boxes represent follow-up times and red boxes denote the associated clinical-instrumental status. MSH6, clone 44 Ventana; PD-1, programmed death ligand 1.](mco-12-01-0003-g00){#f1-mco-0-0-1946}

![IHC of primary melanoma. When compared with MLH1, PMS2 and MSH2 levels, an exclusive loss of MSH6 expression was exhibited in a female case of subungual melanoma form the patient cohort, as determined via IHC. In the remaining cases of cutaneous melanoma, the expressions of MLH1, PMS2, MSH2 and MSH6 were within the normal range (scale bars, 100 µm). IHC, immunohistochemistry; MLH1, clone M1 Ventana; PMS2, clone EPR3947 Ventana; MSH2, clone G219-1129; MSH6, clone 44 Ventana; H&E, hematoxylin and eosin.](mco-12-01-0003-g01){#f2-mco-0-0-1946}

![IHC of metastasis. Ileal metastasis tumor originating from subungual melanoma exhibits the same IHC profile of primitive neoplasia. It is characterized by an exclusive loss of expression of MSH6 protein when compared with MLH1, PMS2 and MSH2 status. In the analyzed metastases of the current cohort (e.g., gastric metastasis), the expression of MSH6 protein was preserved as with that of MLH1, PMS2 and MSH2 (scale bars, 100 µm). IHC, immunohistochemistry; MSH6, clone 44 Ventana; MLH1, clone M1 Ventana; PMS2, clone EPR3947 Ventana; MSH2, clone G219-1129; H&E, hematoxylin and eosin.](mco-12-01-0003-g02){#f3-mco-0-0-1946}

###### 

Clinical and pathological features of the patient cohort.

  Patient   Sex   Age (years)   Location of the primary MM   Breslow   BRAF status   Metastasis sites                                TNM stage before anti PD-1 therapy   Line of therapy   Start of anti PD-1 therapy   Last follow-up   Status   Type of response   OS (days)   PFS (days)   MMR status
  --------- ----- ------------- ---------------------------- --------- ------------- ----------------------------------------------- ------------------------------------ ----------------- ---------------------------- ---------------- -------- ------------------ ----------- ------------ -------------------------
  1         M     82            Back                         2         V600E         Skin, lungs, perirenal                          4b                                   I                 19/05/16                     11/07/17         Alive    CR                 572         418          MMR stable
  2         M     84            Head and neck                11        WT            Skin, lymph node                                3c                                   II                14/04/16                     16/08/16         Dead     PD                 154         124          MMR stable
  3         M     83            Upper limbs                  4         WT            Lungs, lymph node                               4b                                   I                 12/07/16                     26/11/16         Dead     PD                 213         81           MMR stable
  4         M     73            Back                         2         WT            Lung, bone, spleen, liver, lymph node           4c                                   I                 07/07/16                     27/06/17         Alive    PR                 406         355          MMR stable
  5         M     83            Lower limbs                  3         WT            Lymph node, muscle, retroperitoneal             4a                                   I                 21/08/16                     11/07/17         Alive    CR                 335         324          MMR stable
  6         M     55            Back                         15        V600E         Lymph node, skin                                4a                                   II                13/05/16                     19/11/16         Dead     PD                 1,040       125          MMR stable
  7         F     76            Lower limbs                  7         WT            Skin                                            4a                                   II                15/03/16                     11/07/17         Alive    PD                 719         457          MMR stable
  8         M     57            Back                         4         V600K         Lymph node, lungs, skin, liver, spleen, brain   4c                                   II                15/05/16                     03/09/16         Dead     PD                 201         93           MMR stable
  9         M     86            Acral                        2         WT            Lungs, pancreatic, pararenal                    4d                                   II                28/01/16                     12/10/16         Dead     PD                 368         196          MMR stable
  10        M     77            Back                         3         WT            Lungs, lymph node, bowel, muscle                4b                                   III               15/09/14                     19/09/16         Dead     PD                 1,496       517          MMR stable
  11        F     48            Acral                        1,4       WT            Kidney, lymph node, lungs, bone, brain, bowel   4d                                   V                 21/11/14                     04/07/17         Alive    CR                 2,546       956          Loss of MSH6 expression
  12        M     57            Chest                        13        V600E         Skin, liver, spleen, lungs, bone                4c                                   II                11/10/16                     11/07/17         Alive    PD                 94          84           MMR stable
  13        M     47            Chest                        3         V600E         Lungs                                           4b                                   I                 23/08/16                     11/07/17         Alive    PR                 361         322          MMR stable
  14        M     88            Head and neck                11        WT            Lungs, brain                                    4d                                   III               18/06/15                     01/07/17         Dead     PR                 1,088       684          MMR stable

M, male; F, female; WT, wild-type; V600E, substitution of valine to glutamic acid at codon 600; c.1799 T\>A; V600K, substitution of valine to lysine at codon 600; c.1798_1799 GT\>AA; CR, complete response; PD, anti PD-1; MM, malignant melanoma; OS, overall survival; PFS, progression-free survival; PR, partial response, Breslow, Breslow levels; MMR, mismatch repair status.
